Calcitonin: current concepts and differential diagnosis.
Level 5 - mechanism / opinion, no new human data
Narrative review of diagnostic concepts and physiological mechanisms without systematic search methodology
PubMed 35614985 · doi:10.1177/20420188221099344
What was done
This narrative review summarizes current concepts regarding calcitonin biosynthesis, receptor signaling, and clinical interpretation. It evaluates the diagnostic role of basal and stimulated calcitonin in medullary thyroid carcinoma (MTC) and reviews benign and malignant differential diagnoses of hypercalcitoninemia.
What was found
Basal calcitonin (bCT) levels >100 pg/ml have up to 100% positive predictive value for MTC. Intermediate levels (8–100 pg/ml for adult males; 6–80 pg/ml for adult females) may require provocative stimulation testing using calcium or pentagastrin, where stimulated calcitonin <2 times bCT is generally not suggestive of MTC. Elevated calcitonin also occurs with non-thyroidal causes, including renal insufficiency, medications (such as beta-blockers), and extrathyroidal malignancies (pancreatic, laryngeal, and lung neuroendocrine neoplasms, as well as selected non-neuroendocrine cancers).
Why it matters
It outlines practical sex-specific cutoff ranges for calcitonin interpretation and clarifies when hypercalcitoninemia points to non-thyroidal pathology rather than MTC.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal of included studies, and quantitative pooling. Assay-specific variability across modern high-sensitivity immunoassay platforms is not quantified in the abstract.
Cited by
- supports In addition to T4, the thyroid gland produces calcitonin and triiodothyronine (T3).